Sepideh KarkonShayan

Dr. Sepideh KarkonShayan


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2023 in Acta Histochemica
Verified
Journal Article
Closed access
SKSepideh KarkonShayan
Sepideh KarkonShayan
HAHasan Aliashrafzadeh
Hasan Aliashrafzadeh
HDHassan Dianat-Moghadam
Hassan Dianat-Moghadam
NRNima Rastegar-Pouyani
Nima Rastegar-Pouyani
MMMohammadreza Majidi
Mohammadreza Majidi
EJEmad Jafarzadeh
Emad Jafarzadeh

13 August 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
AAAmir R. Afshari
Amir R. Afshari
AMAli Motamed-Sanaye
Ali Motamed-Sanaye
HSHamed Sabri
Hamed Sabri
ASArash Soltani
Arash Soltani
SKSepideh KarkonShayan
Sepideh KarkonShayan
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
The current standard of care in glioblastoma multiforme (GBM), as the most morbid brain tumor, is not adequate, despite substantial progress in cancer therapy. Among patients receiving current standard treatments, including surgery, irradiation, and chemotherapy, the overall survival (OS) period with GBM is less than one year. The high mortality frequency of GBM is due to its aggressive nature, including accelerated growth, deregulated apoptosis, and invasion into surrounding tissues. The understanding of the molecular pathogenesis of GBM is, therefore, crucial for identifying, designing, and repurposing potential agents in future therapeutic approaches. In recent decades, it has been apparent that several neurotransmitters, specifically substance P (SP), an undecapeptide in the family of neuropeptides tachykinins, are found in astrocytes. After binding to the neurokinin-1 receptor (NK-1R), the SP controls cancer cell growth, exerts antiapoptotic impacts, stimulates cell invasion/metastasis, and activates vascularization. Since SP/NK-1R signaling pathway is a growth driver in many cancers, this potential mechanism is proposed as an additional target for treating GBM. Following an evaluation of the function of both SP and its NK-1R inhibitors in neoplastic cells, we recommend a unique and promising approach for the treatment of patients with GBM.

8 December 2023 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
LZLing Zhang
Ling Zhang
SPSeyed Abbas Pakmehr
Seyed Abbas Pakmehr
RSReza Shahhosseini
Reza Shahhosseini
MHMaryam Hariri
Maryam Hariri
AFAzadeh Fakhrioliaei
Azadeh Fakhrioliaei
SKSepideh KarkonShayan
Sepideh KarkonShayan

21 April 2025 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
明邵明辰 邵
明辰 邵
MRMohamad Rahmdel
Mohamad Rahmdel
SKSepideh KarkonShayan
Sepideh KarkonShayan
EHElham Hassannia
Elham Hassannia
MKMohammad Khedmatgozar
Mohammad Khedmatgozar
SHSina Hamzehzadeh
Sina Hamzehzadeh

23 April 2024 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
ASAlborz Soroush
Alborz Soroush
SPSiavash Pourhossein
Siavash Pourhossein
DHDorrin Hosseingholizadeh
Dorrin Hosseingholizadeh
AHAhmed Hjazi
Ahmed Hjazi
RSReza Shahhosseini
Reza Shahhosseini
SKSepideh KarkonShayan
Sepideh KarkonShayan

1 October 2023 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
SNSara Abdalrazzaq M. Noraldeen
Sara Abdalrazzaq M. Noraldeen
IRIrodakhon Rasulova
Irodakhon Rasulova
RLRepudi Lalitha
Repudi Lalitha
FHFarah Hussin
Farah Hussin
Hashem AlsaabHashem Alsaab
Hashem Alsaab
SKSepideh KarkonShayan
Sepideh KarkonShayan